Community-based Neuroendocrine Tumor (NET) Research Study

Time to disease progression

Time frame · From first date of lanreotide to up to 24 months (approximately) after the last patient is randomised

Time to disease progression will be defined as the time from the first date of lanreotide, which may have occurred prior to study entry, to the date of first documented disease progression or the date of tumor-related death. In a living patient with no documented disease progression, or if the patient is lost to follow-up, disease progression will be censored at the date of the last evaluable scan. Patients who start a new treatment before they progress will be censored as of the date of last scan. Disease progression is defined for this study as both clinical dimensions of progression in conjunction with a treatment change.

Overall survival

Time frame · From first date of lanreotide to up to 24 months (approximately) after the last patient is randomised

Overall survival will be defined as the time from the first date of lanreotide, which may have occurred prior to study entry, to the date of death due to any cause or the last date the patient was known to be alive.

Adverse events

Time frame · Duration of the study, up to 24 months

Change in flushing and diarrhea

Time frame · Baseline, month 6, 12, 18, 24, end of treatment visit (+/-28 days from patients off treatment)

To be assessed as present or not, and if present, as mild, moderate, or severe. At subsequent visits, it should be noted whether these symptoms are better, worse, or the same as at previous visit.

Patient satisfaction with treatment

Time frame · Month 6, 12, 18, 24, end of treatment visit (+/-28 days from patients off treatment)

Treatment Satisfaction Questionnaire for Medication (TQSM-9)